News

People with dementia, including those with Alzheimer’s disease, often are also living with one or more other chronic diseases  that significantly impact their quality of life, according to a new study. The study, “The impact of comorbidity on the quality of life of people with dementia: findings from the…

Increasing evidence places beta-amyloid aggregates at the center of the toxic protein clumps and neuroinflammation that drive Alzheimer’s, two experts in this disease said, and a personalized, combination treatment likely will be the best way of helping patients. These insights were shared at a recent Key Opinion Leader luncheon meeting,…

A retired U.S. executive has given $5 million to the University of Texas at San Antonio (UTSA) College of Sciences to establish a contest that challenges scientists to find the cause of Alzheimer’s disease, building on work begun by pioneering neuroscientist Oskar Fischer more than a century…

Chronic, low-level inflammation enhances the risk of Alzheimer’s disease among ApoE4 gene carriers, the major genetic risk factor for the late-onset form of the disorder, a study shows. The study, “Association of Chronic Low-grade Inflammation With Risk of Alzheimer Disease in ApoE4 Carriers,” was published in the journal JAMA Network Open.

Herpes simplex virus type 1 (HSV1) may be linked to Alzheimer’s development, and antiviral therapies lower the risk of senile dementia in patients with severe herpes infections, according to a review study. The research, “Corroboration of a Major Role for Herpes Simplex Virus Type 1 in Alzheimer’s Disease,”…

Continued activity improves physical health in older adults at risk of Alzheimer’s, which in turn can potentially reduce their risk of developing the disease, according to results of an Australian clinical trial. The study, “A Randomized Controlled Trial of Adherence to a 24-Month Home-Based Physical Activity Program…

Treatment with Anavex‘s investigational therapy Anavex 2-73 significantly reduces cognitive decline in people with Alzheimer’s disease and sustains their ability to perform daily activities, according to interim data from a Phase 2 extension study. Trial results were presented in a late-breaking oral presentation, titled “Longitudinal 148-Week Extension Study…

Neuralstem’s stem cell therapy for Alzheimer’s disease was found to improve cognition and lessen the load of amyloid-beta plaques in a mouse model of the disease, a study reports, recommending work continue into this possible Alzheimer’s treatment. The therapy, called NSI-532.IGF1, combines human neural stem cells with IGF1, a…

CavoGene LifeSciences is going to explore a new gene therapy, called SynCav1, that may represent an alternative and attractive strategy to treat several neurodegenerative diseases, including Alzheimer’s. This follows CavoGene’s acquisition of SynCav1’s developmental and commercialization rights from the University of California San Diego. SynCav1 was designed to specifically…

Commonly used antidepressants known as selective serotonin reuptake inhibitors, or SSRIs, can prevent beta-amyloid aggregation, representing a potential new therapeutic strategy for Alzheimer’s disease, a study suggests. The study, “Interactions of Selective Serotonin Reuptake Inhibitors with β-Amyloid,” was published in ACS Chemical Neuroscience.